Prothena Corp PLC (PRTA)

52.50
NASDAQ : Health Care
Prev Close 51.76
Day Low/High 51.71 / 53.03
52 Wk Low/High 33.53 / 68.18
Avg Volume 315.40K
Exchange NASDAQ
Shares Outstanding 37.19M
Market Cap 1.92B
EPS -4.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Biotech Premarket Movers: Karyopharm, Lexicon, Prothena

Biotech Premarket Movers: Karyopharm, Lexicon, Prothena

Karyopharm Therapeutics falls 18%; Lexicon rises on drug approval.

First-In-Human Assessment Of PRX002, Prothena's Anti-Alpha Synuclein Antibody For Parkinson's Disease, Published In Movement Disorders Journal

First-In-Human Assessment Of PRX002, Prothena's Anti-Alpha Synuclein Antibody For Parkinson's Disease, Published In Movement Disorders Journal

Data Previously Presented in 2015 at 19th International Congress of Parkinson's Disease and Movement Disorders

Prothena (PRTA) Is Today's Perilous Reversal Stock

Prothena (PRTA) Is Today's Perilous Reversal Stock

Trade-Ideas LLC identified Prothena (PRTA) as a "perilous reversal" (up big yesterday but down big today) candidate

Prothena (PRTA) Flagged As Strong On High Volume

Prothena (PRTA) Flagged As Strong On High Volume

Trade-Ideas LLC identified Prothena (PRTA) as a strong on high relative volume candidate

Today's Dead Cat Bounce Stock: Prothena (PRTA)

Today's Dead Cat Bounce Stock: Prothena (PRTA)

Trade-Ideas LLC identified Prothena (PRTA) as a "dead cat bounce" (down big yesterday but up big today) candidate

16 Biopharma Companies Besides Medivation That Are Attractive Targets

16 Biopharma Companies Besides Medivation That Are Attractive Targets

Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.